Cargando…
The efficiency and safety of immune checkpoint inhibitors for advanced biliary tract cancers based on gene profiles: A retrospectively controlled study
Immune checkpoint inhibitors are potential agents to improve the survival of advanced biliary tract cancers (ABTCs). The current results are controversial because the predictors are imprecise. We present our primary experience with ABTCs based on gene landscape with exciting outcomes. ABTCs who were...
Autores principales: | Yao, G.L., Fan, Y.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478330/ https://www.ncbi.nlm.nih.gov/pubmed/36123922 http://dx.doi.org/10.1097/MD.0000000000030443 |
Ejemplares similares
-
Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022) -
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023) -
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Seesaha, Poshita-Kumari, et al.
Publicado: (2021) -
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
por: Kim, Hongsik, et al.
Publicado: (2022) -
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer
por: Czink, Elena, et al.
Publicado: (2017)